Mexico ADHD Therapeutic Market Analys Sample Report

1. A sample report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutics Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point-of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market , and offers unmatched value, accuracy, and expert insights

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

4. Table of Content CONTENT PG. NO. 13-25 1. ADHD (Attention Deficit Hyperactivity Disorder) Overview 1.1. Overview 1.2. Mexico Overview 1.3. Economic Overview: Mexico 1.4. ADHD (Attention Deficit Hyperactivity Disorder) Market in Mexico 1.5. Pharmaceuticals Market in Mexico 1.6. Healthcare Scenario in Mexico 1.7. Health Insurance Coverage: Mexico 1.8. Budget of the Government for Public Insurance 1.9. Attention Deficit Hyperactivity Disorder Market News 26-32 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. By Medication 2.2.2. By Psychotherapy 2.2.3. By Education or Training 2.2.4. By Age Group 33-37 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Driver 1 3.1.2. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Driver 2 3.1.3. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Driver 3 3.2. Market Restraints 3.2.1. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Restraint 1 3.2.2. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Restraint 2 5 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

6. Table of Content CONTENT PG. NO. 3.2.3. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Restraint 3 38-48 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Janssen of J&J 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Eli Lilly 4.2.2.1. Overview 6 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Neos Therapeutics 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. Pfizer 4.2.4.1. Overview 7 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Noven Pharmaceuticals 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Teva 4.2.6.1. Overview 8 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Novartis 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. Shire plc 4.2.8.1. Overview 9 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Liomont 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. Silanes 4.2.10.1. Overview 10 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 49-46 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 5.4 Reimbursement Process – Medicare 5.5 Reimbursement Process - Medicaid 57-82 6. Methodology & Scope 11 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

12. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis 1. ADHD (Attention Deficit Hyperactivity Disorder) Overview

13. 1.1 Statistics at a Glance: The Burden of ADHD (Attention Deficit Hyperactivity Disorder) in the World Prevalence of ADHD (Attention Deficit Hyperactivity Disorder) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 2.58% Overall prevalence of ADHD worldwide 2.2% (range, 0.1–8.1%) prevalence of ADHD overall in <18 years worldwide In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 50–65% of Individuals ADHD persist into adulthood 1 in 20 children affected ADHD in the US In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 62% Children taking ADHD medication in US 47% Children received behavior treatment in US Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 13 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

14. 1.1 Statistics at a Glance: The Burden of ADHD (Attention Deficit Hyperactivity Disorder) in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia Market -Fastest CAGR Africa Egypt Market ~$xx Bn Market ~Market Size of $xx Bn Illustrative Illustrative 14 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

15. 1.2 Mexico Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 126.7 Mn Is the population of Mexico, in 2022 $10,927.3 Is the Gross Domestic Product (GDP) in Mexico in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 30.3 years Is the median age in Mexico, in 2022 $10,046 per capita was the amount of national health expenditures in 2021 Illustrative Illustrative 15 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

16. 1.3 Economic Overview: Mexico Population of Mexico, (2020-2030) GDP of Mexico, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

17. 1.4 Statistics at a Glance: The Burden of ADHD (Attention Deficit Hyperactivity Disorder) in Mexico Prevalence of ADHD (Attention Deficit Hyperactivity Disorder) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 3-5% of school-aged children can be diagnosed with ADHD in Mexico 25% of the affected children's parents recognize conduct or emotional problems in Mexico In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Mexico ▪ 30% of all ADHD cases in clinical pediatric settings in Mexico 1.5 Mn Instances of ADHD in Mexico In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 25% of the affected children's parents recognize conduct or emotional problems in Mexico 13% receive mental health care in Mexico Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 17 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

18. 1.5 Pharmaceuticals in Mexico Mexico Pharmaceutical Market Forecast, 2022-2030 (in $Bn) XX XX XX XX XX XX XX XX XX 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Pharmaceuticals market in Mexico, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

19. 1.6 Healthcare Scenario in US Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

20. 1.6 Healthcare Scenario: SCD Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

21. 1.7 Health Insurance Coverage: US % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

22. 1.8 Budget of Mexico Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

24. 1.9 Attention Deficit Hyperactivity Disorder Market News (continued) Latest Deals In Mexico Company Name Year Key Pointers Neos Therapeutics reported the United States release of Adzenys XR-ODT, the first orally disintegrating medication for the treatment of ADHD in patients 6 and older ▪ March 2022 Noven received Food and Drug Administration approval for Xelstrym (dextroamphetamine) transdermal system for the treatment of attention- deficit/hyperactivity disorder (ADHD) for adults and pediatric patients 6 years and older ▪ February 2022 24 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

25. 1.9 Mergers and Acquisitions(continued) Latest Deals In Mexico Company Name Year Key Pointers xx 2022 xx 2022 Illustrative Illustrative 25 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

26. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis 2. Market Size and Forecasting

27. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Mexico ADHD Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Mexico Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Mexico Market Size (Bn $) 61 74 84 87 91 95 99 106 Illustrative Illustrative 27 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

28. 2.2 Snapshot of ADHD Therapeutics Market Segmentation By Education or Training By Medication By Psychotherapy By Age Group Pediatric And Adolescent Parent Management Training Stimulants Behaviour Therapy Cognitive Behavioural Therapy Non-Stimulants Social Skills Training Adult Interpersonal Psychotherapy School-Based Interventions Family Therapy In this section you will get an understanding of the segmentations which will cover the Mexico ADHD Therapeutics Market In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ ▪ 28 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

29. 2.2.1 Market Segmentation: By Medication Type Mexico ADHD Market Share, By Medication Type (2022) Stimulants market in Mexico is a significant component of the overall ADHD treatment market ▪ It has the maximum market share in Mexico ADHD market with approximately xx% ▪ Non-Stimulants 32% Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Stimulants 68% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 29 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

30. 2.2.2 Market Segmentation: By Psychotherapy Mexico ADHD Market Share, By Psychotherapy Type (2022) Blood cancer market in Mexico is a significant component of the overall cancer market ▪ Behavioural therapy It has the maximum market share in Mexico cancer market with approximately 42% ▪ Family therapy Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Cognitive Behavioural therapy In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Interpersonal psychotherapy 30 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

31. 2.2.3 Market Segmentation: By Education or Training Mexico Cancer Market Share, By Education or Training (2022) Parent management training has the maximum market share in Mexico cancer market with approximately xx% ▪ School-based interventions Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Parent management training Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Social skills training 31 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

32. 2.2.1 Market Segmentation: By Age Group Mexico ADHD Market Share, By Age Group (2022) Pediatric & Adolescent market in Mexico is a significant component of the overall ADHD treatment market ▪ It has the maximum market share in Mexico ADHD market with approximately xx% ▪ Adult Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Pediatric & Adolescent Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 32 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

33. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis 3. Market Dynamics

34. 3.1 Market growth drivers 3.1.1 Incidence of ADHD is increasing in Mexico, with more than 1.5 Mn new ADHD cases expected to be diagnosed in 2023 Incidence of cancer is increasing in Mexico, with more than 1.8 Mn new cancer cases expected to be diagnosed in 2023 ▪ Incidence of Cancer in Mexico This is driving the demand for cancer treatments and creating opportunities for growth in the cancer market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 34 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

35. 3.1 Market growth drivers (continued) 3.1.2 Death rate from cancer in Mexico has declined by 31% from 1992 to 2022, largely due to advances in technology and treatment options Top countries that are leveraging technology in their fight against cancer Mexico has a long history of investing in cancer research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to cancer treatment and research ▪ Austria Denmark Belgium Spain Italy One of the key factors that has allowed Mexico to stay ahead in the field of cancer research and treatment is the high level of investment in cancer-related research ▪ Netherlands Sweden Singapore Switzerland Israel In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Australia Canada France Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 35 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

36. 3.1 Market growth drivers (continued) 3.1.3 In 2021, the National Cancer Institute (NCI) received $6.4 Bn in funding from Mexico federal government to support cancer research and training programs Fundings from government and other organizations Mexico government provides significant support and funding for cancer research and treatment, which is driving innovation and growth in the cancer market ▪ Source Year Fund ($) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ National Cancer Institute (NCI) 2021 $ 6.4 Bn In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Centers for Disease Control and Prevention (CDC) 2021 $ 501 Mn Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ American Cancer Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn Illustrative Illustrative 36 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

37. 3.2 Market restraints 3.2.1 In 2020, the average cost of a new cancer drug was over $150,000 per year 3.2.2 Average cost of developing a new cancer drug that is ultimately approved by the FDA is over $2.6 Bn 3.2.3 Demand for cancer care is expected to increase by 42% by 2025, while the supply of oncologists is only expected to increase by 28% Cancer treatments can be very expensive and can lead to financial burden for patients and healthcare systems Cost of cancer treatment varies depending on the type of cancer, stage of cancer, and treatment options Some common cancer treatments, such as chemotherapy and radiation therapy, can cost tens of thousands of dollars Regulatory requirements for cancer treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as Mexico Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new cancer treatments This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of oncologists in Mexico, which can limit access to cancer treatments and create barriers to growth in the cancer market Oncologists are physicians who specialize in the diagnosis and treatment of cancer With the aging population and the increasing incidence of cancer, there is a growing demand for oncologists However, the supply of oncologists is not keeping pace with the demand ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 37 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

38. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis 4. Competitive Landscape

39. 4.1 Major Market Share Mexico cancer market is a highly competitive space, with many companies developing and marketing cancer treatments ▪ Revenue of Major players in Mexico Cancer Market ($ Mn) Other Some of the top companies in Mexico cancer market based on revenue and market share include ▪ Roche is a Swiss multinational healthcare company that develops and markets cancer treatments, including targeted therapies and immunotherapies ▪ In 2020, Roche's oncology sales were approximately $24 Bn, making it one of the largest players in Mexico cancer market ▪ XX Illustrative Illustrative 39 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

40. 4.2 Key Company Profile Key Note: 1 Janssen of J&J Here is the list of top 10 companies which will cover in the final report ▪ 2 Eli Lilly Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Neos Therapeutics o o 4 Pfizer o o 5 Noven Pharmaceuticals o 6 o Teva o 7 Novartis o 8 Shire plc ▪ 9 Liomont ▪ 10 Silanes 40 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

41. 4.2.1 Teva Pharmaceuticals ▪ Teva offers the world’s largest medicine cabinet - a full spectrum of products from generics, API and over-the-counter products to specialty and biologic treatments ▪ have a portfolio of more than 3,600 medicines, and produce approximately 76 billion tablets and capsules a year ▪ Teva is a leading supplier of medications on the World Health Organization’s Essential Medicines List (EML), which includes important drugs that address key healthcare needs ▪ Teva launched 5 access to medicines programs as of 2022 Therapeutics offered by Teva Founded in: 1901 ➢ Respiratory HQ: Israel ➢ Migraine, Headache and Pain Type: Private ➢ Neurodegenerative Conditions and Movement Disorders Revenue: $14.9 Bn Website: www.tevapharm.com ➢ Oncology Drugs for ADHD Recent Activity / Press Coverage Drugs Indications Teva Pharmaceuticals began facing supply issues in August 2022, with both ADHD drugs, Adderall and generic amphetamine mixed salts on backorder due to “packaging capacity constraints” and worker shortages. Adderall (amphetamine- based stimulant) Attention deficit hyperactive disorder The shortage comes as ADHD diagnoses and Adderall prescriptions steadily increase — diagnoses more than doubled between 2007 and 2016 INTUNIV (guanfacine nonstimulant medication ) Attention deficit hyperactive disorder Adderall prescriptions rose more than 10% between 2020 and 2021 41 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

42. 4.2.1 Teva (continued) Partnerships Ecosystem Major Research & Acedemic Partners Major Partnerships ▪ Teva found immense scientific merit and strength in the Israeli academic ecosystem. In a joint academia-industry effort, Teva already has some 30 projects underway ▪ In 2021,Teva and Bioeq Announce Commercial Partnership for Biosimilar ▪ This strategic partnership combines Teva’s long-standing commercial presence, extensive distribution network and wide- reaching sales and marketing activities across Europe and international markets ▪ The Hebrew University of Jerusalem, Tel Aviv University (TAU), the Technion (Israel Institute of Technology), and the Weizmann Institute are among the universities and research institutes participating in these projects ▪ Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market ▪ The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry ▪ Teva is partnering with researchers at leading academic institutions in Israel to discover the next breakthrough drug that can help in the fight against cancer, brain diseases 42 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

43. 4.2.1 Teva (continued) Latest Developments Company Name Type Year Key Pointers Teva and MedinCellAnnounce FDA Approval of UZEDY (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adult ▪ FDA Approval April 2023 In a Phase 3 clinical trial, UZEDY demonstrated up to 80% reduction in risk of schizophrenia relapse versus placebo ▪ MedinCell Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System ▪ Collaboration March, 2023 California’s Desert Oasis Healthcare (DOHC) implements Rimidi’s Respiratory Module for respiratory patient monitoring, based on data collected by Teva’s Digihaler System ▪ Rimidi Teva Enhances ADHD Product Line with Generic INTUNIV in the United States Guanfacine extended-release tablets join Teva’s current generic line of seven ADHD products, ▪ FDA Approval June 2015 ▪ Teva 43 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

44. 4.2.1 Teva (continued) Revenues ($Bn), 2020-2030 According to Teva’s 2022 financial report, the company had revenue of $1,903 Mn only in the international market segment including Latin America in 2022 ▪ 70.9 70.3 Company’s Generic Medicines division which included ADHD drugs generated sales of $1,586 Mn in 2022, in the international market segment ▪ 63.3 Countries in International Markets segment of Teva include highly regulated, pure generic markets, such as Israel, branded generics-oriented markets, such as Russia and certain Latin America markets, and hybrid markets, such as Japan ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 1 2 3 4 Illustrative Illustrative 44 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

45. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 45 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

46. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 46 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

47. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 47 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

48. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 48 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential

49. Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis 5. Reimbursement Scenario

50. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the US cancer market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for cancer treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 50 A Sample Report on Mexico ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis I Confidential